

Special Issue

Advances in Melanoma: From Basic Research to Clinical Management, and Future Horizons Exploitation

Message from the Guest Editor

This Special Issue aims to point out the pros and cons in our current knowledge of melanoma: where we are now and what we still need to reach and improve, from basic research to clinical management. There is great potential to transform how we diagnose and treat patients, especially those in an intermediate stage that are at a higher risk of developing metastasis, which we are currently not able to detect. Placing greater importance on the role of technologies in the search of biomarkers, prognosis assessment, and treatment selection, as well as helping to address research voids, might uncover unmet needs that could be exploited to eventually overcome melanoma in the near future.

Guest Editor

Prof. Dr. Laura Atzori

Chief of Dermatology Clinic, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy

Deadline for manuscript submissions

31 December 2026



Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/215001

Diseases
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diseases@mdpi.com

[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)





Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)



About the Journal

Message from the Editor-in-Chief

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).